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Abstract:  The p38 mitogen-activated protein kinases (MAPKs) are members of discrete signal transduction pathways
that have significant regulatory roles in a variety of biological processes, depending on the cell, tissue and organ type.
p38 MAPKs are involved in inflammation, cell growth and differentiation and cell cycle.  In the female reproductive
system, p38 MAPKs are known to regulate various aspects of the reproductive process such as mammalian estrous and
menstrual cycles as well as early pregnancy and parturition.  p38 MAPKs have also been implicated in alterations and
pathologies observed in the female reproductive system.  Therefore, pharmacologic modulation of p38 MAPKs, and
inter-connected signaling pathways (e.g., estrogen receptor signaling, c-fos, c-jun), may influence reproductive
physiology and function.  This article provides a critical, comparative review of available data on the roles of p38
MAPKs in the mammalian female reproductive system and in reproductive pathophysiology in humans and preclinical
species.  We first introduce fundamental differences and similarities of the mammalian female reproductive system that
should be considered by toxicologists and toxicologic pathologists when assessing the effects of new pharmacologic
agents on the female reproductive system.  We then explore in detail the known roles for p38 MAPKs and related
molecules in female reproduction.  This foundation is then extended to pathological conditions in which p38 MAPKs
are thought to play an integral role.     (J Toxicol Pathol 2009; 22: 109–124)
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Introduction
The p38 mitogen activated protein kinases (MAPKs)
are members of discrete signaling transduction pathways
that play significant regulatory roles in a variety of
biological processes including inflammation, cell
differentiation, and cell growth1–4.  By participating in
phosphorylation cascades, p38 modulates the regulation and
activity of several transcription factors (i.e., activating
transcription factors-1 and -2 (ATF-1, ATF-2); the p53
tumor suppressor protein; and CCAAT/Enhancer Binding
Proteins-beta (C/EBPβ)5–8.  These transcription factors lead
to cytokine production, cell growth, apoptosis, and other
cellular processes.  Therefore, because of p38’s involvement
in inflammation, specific p38 inhibitors are under
development as anti-inflammatory medicines3,9.
p38 MAPKs are activated by dual phosphorylation at
residues thr180 and tyr182.  Some p38 inhibitors (i.e.,
SB203580) compete for the ATP binding pocket and inhibit
direct enzymatic activation, while other inhibitors (i.e.,
BIRB796) stabilize a conformation that is unable to bind
ATP10.
p38 MAPK, along with a variety of intracellular
signaling pathways such as Estrogen Receptor α (ERα), c-
jun and c-fos, orchestrate physiological events in the uterus
during the menstrual cycle in both humans and in preclinical
species such as nonhuman primates (NHPs).  Emerging data
suggests that uterine function effects may be attributable to
the close interrelationships of these signaling pathways and
their modulation11.  c-fos and c-jun interact with the
transcription factor activator protein-1 (AP-1) which
translocates to the nucleus and binds to the AP-1 enhancer
element to initiate a cascade of gene induction events that
lead to cell proliferation12.  MAPKs regulate AP-1
transcriptional activity and c-fos expression in the uterus and
mediates mechanical stretch-induced c-fos expression in
myometrial smooth muscle cells13–16.
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Estrogen stimulates DNA synthesis, and cellular
proliferation and differentiation in the uterus of
mammals17,18.  Binding of estrogen to its receptor (ER)
contributes to uterine cellular proliferation via increased
expression of immediate early response genes13,18–21.  It has
also been suggested that the initial steps in the mechanism of
mitogenesis by estrogen involve activation of c-fos gene
expression in the rat uterus, emphasizing the orchestrated
effort of these molecules in directing uterine function19.
p38 MAPKs are thought to contribute to
parturition15,22,23.  Marked increases in the p38 kinase
activity in the human uterus was observed on day 19 of
gestation and during labor, and declined to the control levels
post-delivery23.  p38 MAPK has also been shown to be
present in endometriotic cells from humans and activated by
pro-inflammatory agents24.  Moreover, various aspects of the
mammalian estrous and menstrual cycles, as well as early
pregnancy, involve regulatory roles for p38 MAPKs5–8,25–28,
and p38 MAPK has been implicated in alterations and
pathologies observed in the female reproductive
system1,12,29.  Considerable “cross talk” between the MAPK
signaling pathways (e.g., p38, JUNK) may also play an
important role throughout all stages of the female
reproductive process.
Collectively, these observations imply a close
interrelationship between ER, c-fos, c-jun, and p38 in
modulating uterine function during the estrous cycle and
early embryonic processes.  Therefore, pharmacologic
modulation of one or more of these signaling molecules,
coupled with interspecies differences in uterine cyclicity,
may influence uterine function.  This article provides a
critical, comprehensive review of the known roles for p38
MAPKs and related pathways in the mammalian female
reproductive system in of humans and in preclinical species,
and signaling in reproductive pathophysiology.  We first
introduce fundamental differences and similarities in the
mammalian reproductive system in humans and in
preclinical species.  We then explore in detail the known
roles for p38 MAPKs pathways in female reproduction.
With this foundation, we then provide a review of the
pathological conditions in the female reproductive system
under which p38 MAPKs may play a role.
Mammalian Estrous and Menstrual Cycles
Much of our knowledge of the female reproductive
cycle is drawn from research conducted on a variety of
species.  The rat, dog, and monkey are common laboratory
animals used for testing new drug candidates developed for
use in human medicine.  However, there are significant
differences among these preclinical species in the female
reproductive system.  Such differences should be taken into
consideration by toxicologists and toxicologic pathologists
when assessing the effects of new pharmacologic agents on
the female reproductive system.
We first introduce these species differences in uterine
cyclicity.  The mechanism of early pregnancy trophoblast
invasion is similar in rodents and the NHPs.  The rat plays a
prominent role in female reproduction research, making it a
good model to detail the mammalian estrous cycle.  There
are significant interspecies differences in uterine cyclicity
that may influence uterine functions and modulate the
signaling pathways of MAPKs, c-fos, c-jun, and/or ER.  For
example, rats exhibit cyclic changes in the expression of c-
fos and ERα11.  The comparative aspects of the estrous cycle
in the rat and dog and menstrual cycle in NHPs and human
are summarized in Table 1 and Figs. 1 and 2.
Rat Estrous Cycle
Rats are continuously polyestrus, with an average
estrous cycle length of 4–5 days.  The cycle is subdivided
into four phases: proestrus (P), estrus (E), metestrus (M)
(diestrus I), and diestrus II (D)30,31.  The P phase begins when
progesterone (P4) levels decline as a result of luteolysis and
follicle-stimulating hormone (FSH) and luteinizing hormone
(LH) secretion from the anterior pituitary.  In the adult
female rat, the concentrations of the preovulatory estradiol
(E2), which is produced by ovarian follicles, peak during the
P phase (Fig. 1).  As E2 levels drop during the E phase, there
is a corresponding lack of glandular and luminal epithelial
growth and, in parallel, an increased apoptosis in these cells.
Stromal cell proliferation is also seen18.  The uterine lumen is
dilated during both the P and E phases.  As a result of the pre-
ovulatory E2 surge, ovulation and mating behavior occur at
the beginning of the M phase.  Notably, of the cell types
comprising the uterus (stromal, epithelial, and myometrial),
only the epithelial cells proliferate in response to E2 in the
adult rat and mouse.  However, all cell types respond in the
immature rodent21.  P4, produced by the newly formed
ovarian corpora lutea, also begins to rise and reaches a
maximum peak during the longest phase of the cycle: the D
phase.  During the D phase, epithelial cell division and
maturation is inhibited, but due to lowered levels of P4 in the
rat, typical endometrial gland secretion is not observed.
The histologic appearance of the uterus varies with the
stage of the reproductive cycle.  The P phase is characterized
by distention of the uterine lumen with clear fluid and the
lumen is usually lined by large low columnar cells31.
Smooth muscle hypertrophy, endometrial stromal cell
proliferation, stromal edema, proliferation of luminal and
glandular epithelium, and a few mitotic figures are present
during proestrus (Fig. 3A).  In the E phase, the uterine lumen
is lined by very large, tall columnar epithelium.  There is
myometrial hypertrophy, and many of the luminal and
glandular epithelial cells undergo vacuolar degeneration and
necrosis (Fig. 3B)30,31.  In the M phase, the epithelial cells of
the luminal lining are reduced in height, the stroma becomes
denser, and mitotic activity decreases (Fig. 3C)30,31.  During
the D phase, the uterus is quiescent and appears shrunken
with dense endometrial stroma, atrophied myometrium, very
small lumen, and cuboidal glandular and luminal epithelium.
Studies in several species have addressed the role of P4
in the modulation of E2 activity and maintenance of theRadi, Marusak, Morris 111
uterus in a state of quiescence or inactivity23–35.  P4 is
secreted for only a limited time by the rat, unless a
leuteotropic signal from the pituitary is received36.  In rats,
that signal is prolactin, which is released upon cervical
stimulation (copulation)37.  With a new release of pre-
implantation E2 from the ovary, P4 stimulates glandular
secretion, endometrial stromal cell proliferation, and
myometrial transformation.  Furthermore, luminal epithelial
cells undergo differentiation while preparing to receive the
blastocyst.
Interestingly, in the absence of pre-implantation E2 in
pregnant rats at this time, P4 maintains the uterus in a neutral
phase and the blastocyst in dormancy.  Co-activators and
repressors of steroid receptors govern appropriate E2/P4
synergism38.  For example, estrogen receptor (ER) negative
uteri are hypoplastic, while P4 receptor negative uteri are
hyperplastic.  This stringent regulation is required for
appropriate uterine receptivity and embryo implantation in
many species39,40.
MAPK signaling pathways are activated during
implantation in the rat41.  Uterine receptivity, also known as
the window of implantation, is identified by loss of
progesterone (Pgr) gene expression from the epithelia42 and
by expression of a number of extracellular matrix molecules
(e.g., secreted phosphoprotein 1 or osteopontin) and integrin
heterodimers (e.g. αVβ3) that also initiate p38 MAPK
signaling40,43.  If no embryo implantation follows, the uterine
endometrium, via an oxytocin (OT)-mediated mechanism,
produces excess prostaglandin (PG), particularly PGF2α,
which is received by the ovary.  As a result, P4 production is
decreased by the ovary and luteolysis occurs, marking the
end of the D phase.
Human and Nonhuman Primate Menstrual Cycle
There are several benefits to using the NHP, in
particular Old-World monkeys, in female reproduction
studies44,45.  In general, NHP reproductive uterine and
ovarian cycles and circulating steroid binding proteins,
resemble those in humans, although other aspects (i.e., cycle
length, gestation length) are different (Table 1).  Our
discussion draws upon both human and NHP studies, with
species differences noted.  For purposes of this review, NHP
means Old-World monkey of the subfamily Cercopithecinae
(macaques, baboons and their phylogenetic kin).
While the estrous and menstrual cycles have numerous
Table 1. Comparative Aspects of the Estrous Cycle vs. Menstrual Cycle in Human and Animal Species (Days1)
Species Humans Primates Dog Rat
(Cycle length) (28 days) (28–30 days) (120 days) (96–120 hrs)
Cycle phases Proliferative (follicular) 6 to 13 6 to 13 –9 to 9 –12 to 122
Secretory (luteal) 14 to 28 14 to 28 10 to 56 34 to 882
Menses 0 to 5 0 to 5 NA NA
Estrus NA NA 0 to 9 0 to 122
Metestrus NA NA NA 12 to 332
Diestrus NA NA 10 to 56 34 to 882
Anestrus NA NA 57 to 198 NA
Proestrus NA NA 199 to 208 89 to 1002
Ovulation 14 to 15 2 to 3 6 to 122
Luteolysis factor Ovarian PGF2α Ovarian PGF2α Uterine PGF2α Uterine PGF2α
Hormones Peak estrogen 12 to 13 12 to 13 A, E P
Peak progesterone 21 to 24 21 to 24 D D
Early pregnancy Receptivity 20 to 24 20 to 24 3 to 6 72 to 1202
Pregnancy recognition 6 to 9 3 to 5 24 to 25 Post coitum several hrs 
post ovulation
Pregnancy factor HCG HCG None PRL
Conceptus attachment 23 to 26 23 to 26 16 to 18 120 to 1442
Implantation 7 to 9 21 to 23 18 to 204 120 to 1442
Gestation 93 5.3 to 5.63 2.1 to 2.33 0.7 to 0.83
Note the significant interspecies differences in uterine cyclicity.  Such differences may influence uterine functions and pharmacologic
modulation of the signaling pathways of MAPKs, c-fos and/or ER11,30,31,53,117,118,119.  Note: primates means Old-World monkey of the subfamily
Cercopithecinae (macaques, baboons and their phylogenetic kin).
NA=Not applicable; E2=Estrogen; E=Estrus; A=Anestrus; P=Proestrus; P4=Progesterone; D=Diestrus; Mths=Months; hCG=Human chorionic
gonadotropin; PRL=Prolactin-like hormones.
1 All value ranges are provided in days, unless otherwise noted.
2 Values expressed in hours.
3 Values expressed in months.
4 Implantation as such does not occur. 112 p38 MAP Kinases in Female Reproduction
Fig. 1.
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similarities in humans and NHPs, a few primary differences
or conventions should be noted (Table 1).  In contrast to the
estrous cycle, which begins and ends at E phase and/or
ovulation, the menstrual cycle begins and ends at menses,
with ovulation occurring mid-cycle.  Also, while the estrous
cycle uses follicular (P and E phases) and luteal (M and D
phases) phases, the menstrual cycle is most commonly
divided into proliferative (follicular) and secretory (luteal)
phases, which describes endometrial thickness46.  Note that
the proliferative phase occurs prior to ovulation in the
menstrual cycle, although further proliferation does take
place at the beginning of the secretory phase.  Finally,
humans and NHPs slough their endometrium when
conception does not occur, whereas in other mammals it is
reabsorbed.  During the proliferative phase the endometrium
begins to thicken and growth of all endometrial cells
(endothelial, myometrial and stromal) takes place (Fig. 2).
Mitoses are present in the endometrial glandular epithelium
during the follicular (“proliferative”) phase of the cycle, and
in the stroma during the early luteal (“secretory”) phase.  No
evidence of mucus secretion or vacuolation is present during
the proliferative phase.  In the secretory phase, the
endometrium slows its growth, stromal edema is evident,
basal sub-nuclear secretory vacuoles are present in the
glandular epithelium, and there is secretory exhaustion.
Stromal edema is usually present at two times in the
menstrual cycle, once in the mid-follicular/proliferative
phase and once in the mid-luteal/secretory phase11.
However, the menstrual and estrous cycles have more
similarities.  During the follicular phase paralleling the P and
E phases, follicle stimulating hormone (FSH) and luteinizing
hormone (LH) are released from the anterior pituitary under
hypothalamic control, leading to ovarian follicular
recruitment for ovulation and increased E2 production.  The
endometrium thickens and P4 levels are minimal.  The
mature ovarian follicle eventually secretes sufficient E2 to
promote a LH surge, which culminates in ovulation.  Growth
of all endometrial cells (endothelial, myometrial and
stromal) takes place in response to this E2 stimulation.
P4 levels increase in the stroma and remain elevated
throughout the secretory phase, while levels in the
epithelium decrease.  The ruptured ovarian follicle develops
into the corpus luteum and secretes P4 and E2 during the
secretory phase.  P4 suppresses E2 proliferation and causes a
shift in proliferative activity to the stromal cells, which
triggers epithelial cell differentiation in preparation for
implantation.
The changing pattern of E2 and P4 secretion during the
NHP menstrual cycle is essential for the hormonal regulation
of endometrial growth and differentiation, and P4 action is
essential for the proper maturation of the endometrium47.
The transition from a proliferative (E2-dominated) to
secretory (P4-dominated) endometrium results in the
appropriate differentiation that permits implantation47.  In
NHP, P4 primes the stromal cells to respond to pre-
implantation (nidatory) E2 for decidualization in early
pregnancy.  Stromal cell proliferation during the menstrual
cycle is reported into the early to mid-secretory phase, when
the endometrium reaches maximum thickness.  Unlike the
rat, P4 levels in humans and NHPs produce glandular
secretory activity.  A pre-decidualization process,
manifested by stromal edema, can be seen, as early as 10
days following the LH surge in humans.  The reaction is
characterized by eosinophilic and enlarged stromal cells that
begin to surround prominent spiral arteries.  Over the
subsequent 3–4 days, this reaction spreads to the upper two
thirds of the endometrium48, preparing a suitable
environment for embryo attachment, successful
implantation, and protection from invasive trophoblasts of
the mother.  Notably, pre-decidualization is part of the
normal human menstrual cycle and the late luteal phase of
macaque endometrium show decidual changes48,49.
Fig. 1. Rat estrous cycle and differences in p38, c-fos and ER expression during various stages of the cycle.  The average estrous cycle length in
rats is 4–5 days.  The cycle is subdivided into four phases: proestrus, estrus, metestrus, and diestrus.  The proestrus phase begins when
progesterone (P4) levels decline as a result of luteolysis and follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion
from the anterior pituitary.  In the adult female rat, preovulatory estradiol (E2), which is produced by ovarian follicles, concentration peaks
during the proestrus phase.  As a result of the pre-ovulatory E2 surge, ovulation occur during the estrus phase.  In proestrus, endometrial
stromal cell proliferation, stromal edema, and proliferation of luminal and glandular epithelium with subsequent increase in endometrial
thickness take place.  Myometrial hypertrophy also is seen during estrus.  In the metestrus and diestrus phases, the luminal lining epithelial
cells are reduced in height, the stroma becomes denser, and the uterus becomes quiescent with subsequent decreases in endometrial
thickness.  Overall, p38 strongly is upregulated during proestrus, estrus, and metestrus phases.  c-fos is strongly upregulated in proestrus
and metestrus and mildly upregulated in estrus.  ERα expression is highest during proestrus and lowest in metestrus11,30,31,119.
Fig. 2. Human menstrual cycle and differences in p38, c-fos and ER expression during various stages of the cycle.  The menstrual cycle begins
and ends at menses, with ovulation occurring mid-cycle.  The menstrual cycle is divided into proliferative (follicular) and secretory
(luteal) phases, which describes endometrium thickness.  During the follicular phase, follicle-stimulating hormone (FSH) and luteinizing
hormone (LH) release from the anterior pituitary under hypothalamic control, takes place and leads to ovarian follicular recruitment for
ovulation and increased estradiol (E2) production.  The endometrium thickens and progesterone (P4) levels are minimal.  The mature
ovarian follicle eventually secretes sufficient E2 to promote a LH surge, which culminates in ovulation.  Growth of all endometrial cells
(endothelium, myometrium and stroma) takes place in response to this E2 stimulation.  During the proliferative phase, the endometrium
begins to thicken and growth of all endometrial cells takes place.  In the secretory phase, the endometrium slows its growth.  Overall, p38,
c-fos, and ERα are strongly upregulated during the proliferative phase and lack expression in the secretory phase11,53,117.114 p38 MAP Kinases in Female Reproduction
In primates, the ovarian cycle is uterine independent
whereas it is uterine dependent in subprimate mammals.
Luteolysis is driven by the withdrawal of the ovarian
steroids, E2 and P4, and release of PGF2α.  PGF2α is released
by the uterus in rats and other mammals, and the ovaries in
NHPs37.  Mediation of this luteolytic event by OT, although
controversial, is reported in the NHP and also thought to be
important in the rat37,50, but appears unlikely to play a role in
human menses48,49.  Cytokines, proteases, and PGs also play
a role in menses51,52.
Role of p38 MAPK Signaling Throughout the
Normal Estrous and Menstrual Cycles and Early
Pregnancy
As previously noted, p38 MAPKs are involved in
cytokine and growth factor production, secretion and
receptor signaling, cell growth and differentiation, and the
cell cycle.  All of these processes occur during normal
uterine tissue cycling; therefore, it should not be surprising
that p38 is expressed during both human menstrual and rat
estrous cycles (Figs. 4A-F)11.
PGF2α is a luteolytic factor during the normal cycling in
large animal species, pseudopregnant rodents, and in the
human and NHP menstrual cycle30,53,54.  However, there are
species differences in their luteolytic dependence on OT and
site of PGF2α production (Table 1)37.  Evidence for OT
involvement in luteolysis at late D phase in ruminants is well
established37,55.  By coupling to the G protein, OT promotes
PGF2α synthesis in a manner dependent on the ovarian
steroids and their receptors.  There is indirect and somewhat
controversial evidence for the role of OT in PGF2α
production and luteolysis in the rat37,55.  However, OT
receptor mRNA levels rise during the D phase in the rat
uterus, reaching a maximum during the P phase, which
emphasizes the importance of this receptor during the
proliferative phase.
The mechanism of OT-induced PG synthesis has been
investigated in rat OTR-transfected Chinese Hamster Ovary
(CHO) cells56.  It was found that there are two signaling
pathways triggered by the OT-OTR complex56.  Pathway (a)
is G protein and cyclooxygenase (COX)-2-mediated and
leads to PG synthesis through ERK2 MAPK, but not p38
MAPK activation.  Similarly, PGF2α production in sheep is
shown to be ERK1/2–mediated.  The parallel pathway (b),
regulating free intracellular Ca2+ ion concentrations,
involves coupling to the Gi protein and activation of p38
MAPK.  Notably, a similar OT-OTR triggering event
involving Ca2+ is reported to take place in the myometrium at
the time of parturition in a variety of species.  In contrast,
regulatory events, especially those involving uterine
sensitization to E2 and ERα, are thought to be different than
those events seen during cycling55.  In the rat and human, this
OT-mediated parturition event is modulated by both Gq- and
Gi-coupling proteins.  Thus, although the PGF2α-mediated
luteolysis does not involve p38, other events involving Gi-
OTR coupling during the estrous cycle likely do involve p38.
Fig. 3. Histological appearance of the rat uterus during proestrus (A),
estrus (B), and metestrus (C).  Smooth muscle hypertrophy
(short arrows), endometrial stromal cell proliferation, stromal
edema, and few mitotic figures are present during proestrus
(A).  In estrus (B), the uterine lumen is lined by very large, tall
columnar epithelium, there is myometrial hypertrophy, and
many of the luminal and glandular epithelial cells undergo
vacuolar degeneration and necrosis (long arrows).  In
metestrus (C), the luminal lining epithelial cells are reduced
in height, there is cytoplasmic vacuolation of luminal
epithelial cells (arrowheads), the stroma becomes denser, and
mitotic activity decreases.Radi, Marusak, Morris 115
Extensive remodeling of the endometrium during the
menstrual phase involves repeated tissue breakdown and
regeneration7.  During this time, leukocytes and endometrial
cells secrete cytokines, chemokines, and proteases and also
promote proliferation of endometrial cells,
reepithelialization, and angiogenesis during reconstruction.
These activities are modulated in the endometrium, in part,
by the protease-activated receptor 2 (PAR2) via stimulation
of IL-8 secretion in stromal and epithelial cells, which
induce stromal cell proliferation and activate
metalloprotease 7 in epithelial cells7.  p38 and other MAPKs
have been shown to mediate PAR2 activation and are
therefore critical to the regulation of endometrial
remodeling7.  Furthermore, in the late secretory phase of the
Fig. 4. (A) p38 expression in human uterus during the secretory phase.  No epithelial p38 expression.  (B) p38 expression in nonhuman primate
(Cynomolgus macaque) uterus during the proliferative phase.  Strong glandular epithelial cytoplasmic expression.  (C) p38 expression in
nonhuman primate (Cynomolgus macaque) uterus during the secretory phase.  No epithelial expression.  (D) p38 expression in rat uterus
during proestrus.  Strong glandular and luminal epithelial cytoplasmic expression.  (E) p38 expression in rat uterus during estrus.  Strong
glandular and luminal epithelial cytoplasmic expression.  Note strong myometrial smooth muscle cells cytoplasmic staining.  (F) p38
expression in rat uterus during metestrus.  Strong glandular and luminal epithelial cytoplasmic expression.  Immunohistochemical stain,
original magnification ×10.  Radi ZA, Khan NK, Toxicologic Pathology (34(4)), pp. 327–335, copyright 2006.  Reprinted by Permission of
SAGE Publications.116 p38 MAP Kinases in Female Reproduction
human menstrual cycle, as ovarian steroid levels decrease,
superoxide dismutase (SOD) catalysis of the conversion of
superoxide anion (O2
–) to hydrogen peroxide (H2O2)
decreases, which increases reactive oxygen species (ROS)51.
Increased ROS production activates the nuclear factor kappa
B (NF-κB), an inflammatory response transcription factor,
which is thought to regulate COX-2 and subsequent
synthesis of PGF2α.  In rat skeletal muscle, it was shown that
p38 inhibition impairs contraction-mediated IκB kinase
phosphorylation, the precursor step to NF-κB activation56.
Translationally, it is plausible that p38 plays a role in NF-κB
regulation of PGF2α during luteolysis.
E2-Induced Endometrial Cell Proliferation and
Possible Roles for p38 MAP Modulation: The E2-
ERα complex
Infertility and lack of uterotrophic response has been
reported in ERα knockout mice57.  As previously noted,
endometrial cell proliferation in the rat estrous cycle and
NHP menstrual cycle is triggered by the release of E2 from
developing ovarian follicles.  The ER is a zinc finger-
containing transcription factor and member of the nuclear
receptor superfamily with two isoforms, α and β, which are
differentially expressed in a tissue-dependent manner in the
uterus and ovary, respectively58.  In the uterus, E2 binds to
ERα.  ERα is then targeted to the nucleus where it stimulates
the growth of normal and transformed endometrial cells of
the female reproductive system (Fig. 5).  To facilitate this
activity, ERα is localized in nuclei of uterine cells in a
variety of species11,59,60.
Although ERα predominates over its ERβ analog, ERβ
mRNA and ERβ protein are expressed in the nuclei of
glandular epithelium in rats, macaques, and humans,
suggesting a possible role for this isoform in modulating E2
action61,62.  Furthermore, nuclear receptors are not the only
the key mediators in the female reproductive system.  Non-
genomic membrane ERs, upon E2 binding, can also induce
G-protein activation and MAPK pathways important to
cellular processes (Fig. 5)63–65.
During the proliferative phase of the menstrual cycle,
ERα mRNA and protein are expressed in all major uterine
cells, including glandular epithelial, stromal, and uterine
wall smooth muscle cells (Fig. 6A).  Protein concentrations
of both receptors decline during the secretory phase59.
Similarly in the adult rat, ERα expression is lowest during
the P and E phases, and consistent with cell proliferation
patterns, ERα is only expressed in the glandular and luminal
epithelia (Fig. 6B).  ERα concentration rises significantly in
these cells during the M phase in response to E2 release18,62.
In the luminal epithelial cells, proliferation continues to
rise and although ERα levels drop, ERβ in uterine glandular
epithelium of the rat is debatable18,62.  In NHP uterine
sections, strong endometrial stromal cell nuclear ERα
staining, moderate to strong glandular epithelial nuclear
staining, and mild luminal epithelial and myometrial smooth
muscle cell nuclear staining were seen during the
proliferative phase (Fig. 6C)11.
During the secretory phase, mild glandular epithelial
nuclear staining, negative myometrial smooth muscle cell
and luminal epithelial nuclear staining, and strong
endometrial stromal cell staining are observed.  The
changing pattern of E2 and P4 secretion during the NHP
menstrual cycle is essential for the hormonal regulation of
endometrial growth and differentiation and P action is
essential for the proper maturation of the endometrium47.
The transition from a proliferative (E2-dominated) to
secretory (P4-dominated) endometrium results in the
appropriate differentiation that permits implantation47.  The
numbers of ER in non-human primate endometrium are low
when serum P4 levels are elevated during the secretory phase
of the menstrual cycle, but rise two to three fold when P4
levels decline during the proliferative phase66.  In humans,
extracellular signal-regulated kinase 1 (ERK1) is weakly
expressed in glandular cells, but nearly undetectable in
stromal cells of endometrial sections.  ERK2 exhibited
distinct glandular expression in both the proliferative and
secretory phases, and a weak stromal cell expression67.
The mechanism of E2 cell growth stimulation in the
uterus is mediated through the expression of a series of genes
(Fig. 5).  Unlike other ligand-dependent receptors (e.g.,
glucocorticoid receptor), translocation back into the cytosol
is not observed upon E2 binding62, although it is interesting
to note that other non-classical ligands (e.g., the ERα
antagonist, ICI 182,780) can translocate ERα to the
cytoplasm via a p38-mediated mechanism68.
The ligand binding region of ERα has two
transactivating domains, which are thought to act
cooperatively.  These are E2-independent activation function
(AF1) and E2-dependent AF2 domain, located in the N- and
C-terminal regions, respectively69.  When E2 binds to the
AF2 region, a conformational change occurs that permits
receptor binding to co-activating proteins (and co-
repressors) that are necessary for transcription.  Some of
these co-activators include estrogen receptor-associated
protein 160 (ERAP160), a splice variant of the progesterone
receptor (PR) co-activator steroid receptor coactivator-1
(SRC-1) and member of the p160/SRC-type steroid receptor
co-activators, and CBP/p300, a known co-activator of the
nuclear receptor transcription factors cyclic adenosine
monophosphate (cAMP) response element-binding protein
(CREB) and activating protein-1 (AP-1)70.
The E2-independent AF1 domain is thought to be
responsible for tissue and target specificity of the receptor
molecule.  AF1 activation, also leading to co-activator
recruitment, is accomplished by MAPK phosphorylation.
Importantly, direct phosphorylation and activation of ERα
by p38 has been shown in human uterine endometrial cancer
cells, suggesting that a similar mechanism is expected to
play a role in normal uterine cell proliferation69.  MAPKs
have also been shown to phosphorylate ERα71,72 and other
nuclear hormone receptors containing AF1 and AF2
domains (e.g., peroxisomal proliferators activated receptor
[PPAR-γ])73, thereby modulating their activity.Radi, Marusak, Morris 117
By binding to estrogen response elements (ERE), the
nuclear E2-ERα transcription complex enhances the
expression of genes (i.e., PR, OT, OTR) and protooncogenes
(i.e., c-fos, jun [c-jun, jun-B and jun-D] and c-myc)18,19,
regulates other non-ERE factors (i.e., epidermal growth
factor (EGF), insulin-like growth factor (IGF-1) and their
respective receptors, and cyclin D1, a first acting cyclin in
cell cycle regulation and intra-cellular sensor of extracellular
signals)74.
Expression and localization of E2-ERα, c-fos, c-
jun, and c-myc in Rat and Human Uteri
Depending on the tissue type, the nuclear
protooncogenes are key players in cell proliferation,
differentiation, and tumorigenesis, due in part to the direct
effect of E2 on these genes and their direct regulation by p38
MAPK75.  E2-ERα transcription products, c-Fos and c-Jun,
are members of the AP-1 transcription factor complex.
Because increased expression occurs early in E2 signaling,
these genes are called “immediate early genes”.  Notably,
and as it will be discussed, there are differences in
protooncogene expression between primates and other
species during the menstrual cycle.
Following E2 treatment in mice, c-fos expression is
observed only in the glandular and luminal epithelia,
signifying a cell specific proliferative role76.  Mendoza et al.
further detailed c-fos expression in the rat, reporting a rise
and peak in c-fos mRNA in both the glandular and luminal
epithelia during the M phase, with a drop in concentration in
both cells during the D phase.  While c-fos protein
concentrations rise during the M phase, concentrations
increase only slightly during the D phase18.  The rate of c-fos
gene expression parallels that of formation of the active
nuclear E2-ERα complex19.  Studies in p300/CBP-associated
factor (PCAF)–/–/PCAF-B+/– knockout mice have pinpointed
Fig. 5. E2-ERα complex mediate cell proliferation via-p38-mediated
mechanism.  ERα nuclear receptors are only one of the key
actors in the female reproductive system; non-genomic
membrane ERs, upon E2 binding, can also induce G-protein
activation and MAPK pathways important to cell processes
such as cellular proliferation.
Fig. 6. A. ERα expression in human uterus during the proliferative
phase.  Strong glandular (long arrow) epithelial nuclear
expression.  Note strong interstitial and moderate smooth
muscle cell nuclear ER expression (arrowheads).  B. ERα
expression in rat uterus during estrus.  Moderate glandular and
luminal epithelial nuclear expression.  C. ERα expression in
non-human primate (Cynomolgus macaque) uterus during the
proliferative phase.  Strong endometrial stromal cell nuclear
expression and moderate glandular epithelial nuclear staining.
Immunohistochemical stain, original magnification ×10.  Radi
ZA, Khan NK, Toxicologic Pathology (34(4)), pp. 327–335,
copyright 2006.  Reprinted by Permission of SAGE
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the involvement of E2-ERα co-activators p300/CBP and
PCAF in mediating c-fos expression in normal uterine cell
growth76.
P4 appears to have more effect on c-fos mRNA than on
the c-fos protein, a finding also reflected in the mouse75.
Therefore, it is suggested that c-fos may have a role in the
implantation period.
Similarly c-myc mRNA has been shown to rapidly
increase in response to E2 in the rat19, with more specific
distribution details described in the mouse77.  Following E2
injection in ovariectomized mice, c-myc protein was
detected in uterine luminal and glandular epithelial nuclei
during the P phase.  P4 also increased the number of c-myc
positive stromal cells.  Moreover, c-myc was detected in the
nuclei of luminal and glandular epithelial cells during
proestrus and on days 1 and 2 of pregnancy.  These results
suggest c-myc is a potent stimulator of cell proliferation19.
In further contrast to c-fos and c-myc, c-jun is repressed
by the ER in the rat epithelium20,21.  c-jun expression was
decreased in the epithelium and became evident in the
stromal and myometrial cells early after E2 stimulation in
ovariectomized mice75.  This work suggests that other Jun
proteins (i.e., Jun-B, Jun-D) and c-fos may be important in
early epithelial cell proliferation in the rodent.
As might be expected from animal model studies, E2
stimulates c-fos mRNA expression in the human
endometrial epithelium and stroma during the proliferative
phase of the menstrual cycle and occasionally during the
mid-secretory phase78,79.  Additionally, ERα-dependent c-
fos expression in decidual tissue during pregnancy is very
low, paralleling the decline of ERα in these cells and
providing further evidence on the relationship between c-fos
and ERα.
c-myc is also expressed in the human endometrium
during the menstrual cycle.  Unlike in the rat, c-jun
expression is strongly detected in both the proliferative and
secretory phases of the menstrual cycle in humans79.  Bircan
et al. showed, using immunohistochemistry, that c-jun
expression occurs primarily in the proliferative phase of the
menstrual cycle80, which was further supported by Hong et
al. showing a correlation between growth in cultured
endometrial stromal cells and activated c-jun expression81.
AP-1 subunits are dimeric basic region-leucine zipper
(bZIP) proteins that belong to the Jun (c-jun, Jun-B and Jun-
D), Fos (c-fos, Fos-B, Fra-1 and Fra-2), ATF (ATFa, ATF-2
and ATF-3), Maf, and Jun dimerization partner (JDP)
subfamilies and recognize either phorbol-myristate-acetate
(TPA)-response elements (TREs) or cAMP response
elements (CRE) of DNA.  Both Fos and Jun can act
independently as transcription factors, activating
transcription of growth-promoting genes or inhibiting
growth-repressing gene transcription82.
AP-1 regulation of cell processes (i.e., proliferation,
survival, differentiation) is dependent on dimer composition,
cell stimulus, cell type, and cell environment.  MAPKs, such
as p38, contribute to AP-1 regulation by stabilizing the
participating proteins through phosphorylation and
regulating their induction82,83.  For the latter, p38 has been
shown to phosphorylate and activate cis-element binding
proteins important for c-fos induction, including CREB or
ATF (2), which occupy the CRE consensus sequence and
ELK-1, a monomeric ternary complex factor (TCF).  This
TCF is recruited by the serum-response factor (SRF), the
protein that recognizes the serum response element (SRE) in
response to ultraviolet (UV) irradiation and interleukin-1
(IL-1) stimuli.  It is therefore hypothesized that p38 may play
a similar role in AP-1 regulation in uterine cell proliferation.
Cell cycle regulation is carried out by cyclins that bind
to cyclin-dependent kinases (cdks) or cdk inhibitors to
regulate phosphorylation of the retinoblastoma protein
(pRB) and cell cycle progression.  Studies in the murine
system have suggested that a central point of regulation
involves E2-induced uterine epithelial cell proliferation by
nuclear accumulation of Cyclin D1 and pRB activation via a
PI3 kinase/AKT/GSK3β- mediated pathway, which is
inhibited by P4
84.  However, these studies also note the need
for a parallel pathway to initially trigger DNA synthesis.
Correspondingly, the c-jun protein product of E2-ERα
transcription is known to promote DNA synthesis, or the S
phase of the cell cycle, in cultured normal human
endometrial glandular cells via binding to the AP-1
sequence, with subsequent activation of Cyclin D185.  Many
other factors have been shown to play a role in Cyclin D1
regulation in other systems in response to the E2-ERα
interaction, including CREB, ATF-2, c-fos and pS1 in breast
cancer cells.  These studies reveal a host of complex
signalling pathways that are most likely triggered upon E2
and P4 stimulation.  Several pathways can involve p38
MAPK activation.
Role of p38 MAPK Signaling in Stromal Cell
Differentiation and Proliferation During Normal
Menstrual Cycling and Early Pregnancy
The purpose of cell proliferation upon E2 exposure is to
prepare the uterus for embryo implantation where P4 and its
progesterone receptor (PR) are critical.  During the primate
menstrual cycle, PR levels increase in the stroma during the
proliferative phase and remain high during the secretory
phase, while levels in the epithelium decrease with
increasing P4 and during the secretory phase.  Thus, P4
suppresses E2-modulated proliferation via ERα and causes
epithelial cells to differentiate in preparation for
implantation.  Persistence or overexpression of ERα, is
associated with implantation failure and other disorders39.
Fazleabas’ group has detailed early conception in the
non-human primate, describing three phases of uterine
receptivity86.  Phase I of early pregnancy, regulated by E2
and P4, is characterized histologically by the presence of
columnar epithelium with microvilli and an increase in
stromal cell proliferation.  There is a loss of ERα and PR in
the luminal and glandular epithelium, among other
significant endometrial changes.  Loss of receptors for
estrogen and progesterone in uterine epithelia is aRadi, Marusak, Morris 119
prerequisite for implantation and maintenance of
pregnancy87.  Phase II is induced by blastocyst signaling and
is characterized by endometrial changes not observed in the
absence of the blastocyst.  In Phase III, blastocyst attachment
and implantation occurs.  Glandular hypertrophy, increased
permeability of subepithelial capillaries, and stromal cell
decidualization are initiated by the attachment reaction and
are accomplished, in part, by expressed extracellular matrix
proteins.
Pinipode formation characterizes the receptive
endometrium or “implantation window”; and implantation
occurs during the luteal phase (approximately day 21) of the
menstrual cycle (Table 1)88.  In NHPs, in response to embryo
signaling, P4 primes the stromal cells to respond to
preimplantation (nidatory) E2 for decidualization in early
pregnancy.  It has been proposed that NHPs, especially
macaques, may be a valuable experimental animal model to
test the functional role of progesterone-regulated genes on
endometrial receptivity89.  A study on isolated normal and
endometriotic stromal cells showed normal expression of
p38, ERK, and JNK MAPKs, and an increase in p38 MAPK
phosphorylation rate, when stimulated with IL-1β12.  It has
been demonstrated in an endometriosis murine model that a
p38 inhibitor, FR 167653, suppresses the development of
endometriosis90.  This finding suggests an important
regulatory role for p38 in endometrial cell growth.  Indeed, a
modulatory role for p38 in human endometrial stromal cell
differentiation and proliferation in the uterus has been
reported81.  Growth factors from uterine stromal cells
regulate the uterine epithelia, and many of them (e.g.,
fibroblast growth factors-7 and -10, hepatocyte growth
factor) signal via p38 MAPK87.
Another potential role for p38 may be in the regulation
of the p53 protein, a known substrate for p38 evidenced to be
involved in decidualization of the endometrial stroma
critical for embryo implantation2.  The p53 protein is
massively upregulated and sustained during cAMP-induced
decidualization of cultured human endometrial stromal cells,
and expressed in vivo in the stroma during the late secretory
phase of the cycle6.
Successful implantation requires complete stromal cell
decidualization.  As described in human tissue, fibroblast-
like mesenchymal cells differentiate into polygonal decidual
cells that express new proteins such as the insulin-like
growth factor binding protein-1 (IGFBP-1) and prolactin91.
Species differ in embryonic signaling for the onset of
decidualization (Table 1).
Type I and/or type II interferons (IFNs) are important in
establishing uterine receptivity to implantation in
mammals87.  In ruminants, the pregnancy recognition signal,
interferon tau (IFNtau), a type I interferon, prevents
luteolysis by inhibiting the expression of ERα and
subsequently OTR92.  It has been shown in bovine
endometrial cells that IFNtau induces the activation of p38,
implicating a role for this MAPK in establishing and
maintaining pregnancy93.
In the NHP, the release of chorionic gonadotropin (CG)
rescues the corpus luteum and begins preparing the uterus
for implantation.  CG binds to its receptor in the primate
endometrial epithelial cells and has been shown to induce
phosphorylation of the ERK1/2 MAPKs, leading to
expression of COX-2 mRNA and PGE2 production86.  CG
along with the appropriate P4/E2 ratio, only initiates the
process; decidualization is completed through an
inflammatory-like response with the release of numerous
cytokines.
An important and well-studied cytokine, expressed
throughout the menstrual cycle, is Interleukin-1 (IL-1α or
IL-1β).  The expression of its receptor, IL-1 receptor type I,
is low during the proliferative phase, moderate during
ovulation and implantation, and peaks at the end of the
cycle94.  Along with macrophages and uterine epithelial
cells, trophoblast release IL-1, continuing, in the case of
humans, or beginning, in the case of NHP, decidualization of
stromal cells in early pregnancy91.
IL-1β is a major secretory product of the conceptus and
establishment of pregnancy in pigs95.  Following IL-1β
stimulation, a COX-2 pathway leads to PGE2 synthesis, and
is mediated by the p38 MAPK pathway.  The IL-1-p38
mechanism noted above may be similar in other species,
since both PGE2 and PGF2α are known to induce
decidualization in other hormonally-primed species,
including the mouse and rat96,97.
PGE2 is known to play a role in endometrial vascular
permeability, one of the first responses to blastocyst
implantation.  In the rat, vascular permeability, in response
to PGE2, occurs prior to stromal cell decidualization98.
Cyclooxygenases have a pathophysiologic role in various
systems in the body99.  In the murine model, COX-2 was
shown to be important during ovulation, fertilization,
implantation, and decidualization100.  p38 MAPK has been
shown to be crucial to COX-2 expression and the nuclear
hormone receptor PPARδ25.  Expression of COX-2 in the
human endometrium by Prokineticin 1 (PROK1), a recently
described protein that can modulate the inflammatory
process, is dependent on activation of the Gq-phospholipase
C-beta-cSrc-epidermal growth factor receptor-MAPK/ERK
kinase pathway101.  Blocking the COX-2 pathway by
inhibiting p38 MAPK blunts expression of PPARδ and
decreases the decidualization reaction.  Interestingly,
downstream from p38 activation are the ATF, CREB, and C/
EBP factors; known co-activators of the ERα and cis
elements of c-fos, and may be a link between E2 and COX-2
activity.  It has been shown that E2 is involved in the
induction of COX-2 activity during the D phase, as well as
the P and E phases of the estrous cycle in rats102.
In the rat, PGs, including PGI2 (prostacyclin), PGF2α,
and PGE2, play a significant role in the decidualization
response96,103.  PGI2 is thought to be a key player, but PGE2
has been shown to act on four different G protein receptors.
Both COX-1 and COX-2 are found in the epithelial cells of
the endometrium and smooth muscle cells in the circular
layer of the myometrium; expression of COX-2 in the latter
cells increases with IL-1β treatment104.  Further, COX-1 and120 p38 MAP Kinases in Female Reproduction
COX-2 proteins are increased from the non-pregnant D
phase stage to day 18 of gestation, supporting the role of
COX-2 in decidualization during early pregnancy.  As noted
in mice, p38 MAPK most likely mediates the decidualization
process.
IGFBP-1 is a major secretory product in NHP
decidualized endometrium.  It plays a role in trophoblast
invasion as it can stimulate (in the presence of cAMP) or
inhibit (in the absence of cAMP) decidualization48,105.  In the
rat, it has also been shown to be associated with
implantation, modulating the proliferation of uterine cells
and their production of PGI2 during the peri-implantation
period106.  In the baboon, it is known that both p38 and NF-
κB are activated during decidualization, followed by COX-2
and MMP-3 gene expression, which leads to extracellular
matrix degradation, disruption of the cytoskeleton, and
ultimately, IGFBP-1 production107.  A similar MAPK
mechanism may be acting in rats.
Roles of p38 MAPKs Modulation During
Pregnancy and Parturition
P4 maintains the myometrium of the uterus in a state of
quiescence during pregnancy by: 1) inhibiting the expression
of contraction associated proteins (CAPs), which include
connexin 43 and OTR108 and 2) controlling PGF2α, in part,
via modulation of PG dehydrogenase and COX activity109.
These possible roles for p38 have been previously discussed.
IL-β contributes to parturition, by stimulating the
production of PGF2α via a COX-2-mediated mechanism.  As
in the normal cycle, PGF2α induces contraction and
luteolysis.  Takanami-Ohnishi et al. have shown, using
human decidual stromal cells, that this process is mediated
by p38 kinase22.  Both COX-1 and COX-2 are differentially
expressed in the rat uterus, specifically in the epithelial and
myometrial cells, during the estrous cycle, increasing
dramatically during parturition and pregnancy104.  Markedly
up-regulated p38 MAPK activity has also been demonstrated
in the uterus of term-pregnant non-laboring and
spontaneously laboring women. 
Role of p38 MAPKs in Female Reproductive
Pathology
A variety of intracellular signals, including those
involving ERα, c-fos, and p38α, orchestrate physiological
events in the uterus during the secretory and proliferative
phases of the estrous cycle in humans and NHPs.  It is
suggested that p38 has a modulatory role on human
endometrial stromal cell proliferation and differentiation81.
It is known that MAPKs play a role in regulating cellular
hypertrophy and hyperplasia via mechanical stretch of the
uterus15.  Therefore, p38 inhibitors could play a role in
various uterine and cervical proliferative conditions and
cancers, including the pathophysiology of
endometriosis24,110, endometrial, mammary, and ovarian
cancers111–113, leiomyoma, and uterine fibroids114,115.
MAPKs are known to regulate COX-2 expression and
therefore, cervical cancers116.
Conclusions
Toxicologists and toxicologic pathologists need to
consider species differences when evaluating the effects of
new pharmacologic agents on the female reproductive
system.  Experiments conducted on different preclinical
species are not strictly comparable to that of humans because
of significant interspecies differences in the physiology of
uterine cyclicity.  p38 MAPK signal transduction pathways
are interconnected with ER, c-fos, c-jun and jun kinase, and
regulate various aspects of the mammalian estrous and
menstrual cycles, early pregnancy, and parturition.  p38 is
involved in: 1) the OT-OTR-mediated events and luteolysis,
2) regulation of uterine tissue breakdown and regeneration,
3) E2-induced uterine cell proliferation and growth, 4)
implantation and uterine receptivity, and 5) maintenance of
uterine quiescence during pregnancy and onset of
parturition.  Finally, p38 MAPK signaling plays a role in
various pathological conditions in the female reproductive
tract.
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